Top

Published in:

01-07-2007 | Original Article

Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma

Authors: Takashi Yasuda, Takashi Kamigaki, Kentaro Kawasaki, Tetsu Nakamura, Masashi Yamamoto, Kiyonori Kanemitsu, Shiro Takase, Daisuke Kuroda, Yongsik Kim, Tetsuo Ajiki, Yoshikazu Kuroda

Published in: Cancer Immunology, Immunotherapy | Issue 7/2007

Abstract

Cancer immunotherapy by dendritic cell (DC)/tumor cell fusion hybrids (DC/TC hybrids) has been shown to elicit potent anti-tumor effects via the induction of immune responses against multiple tumor-associated antigens. In the present study, we compared the anti-tumor effects of vaccinating Balb/c mice (H-2^d) with CT26CL25 colon carcinoma cells that had been fused with either syngeneic DCs from Balb/c mice, allogeneic DCs from C57BL/6 mice (H-2^b) or semiallogeneic DCs from B6D2F1 mice (H-2^b/d). Preimmunization with either semiallogeneic or allogeneic DC/TC hybrids induced complete protection from tumor challenge, whereas mice preimmunized with syngeneic DC/TC hybrids were only partially protected (75% tumor rejection). The average number of pulmonary metastases after intravenous tumor injection decreased significantly following immunization with semiallogeneic or allogeneic DC/TC hybrids (8.3 ± 7.9 or 16.3 ± 3.5, mean ± SD) relative to syngeneic DC/TC hybrids (67.8 ± 6.3). These data demonstrate that vaccination with semiallogeneic DC/TC hybrids resulted in the greatest anti-tumor efficacy. Anti-tumor effects showed by in vivo studies were virtually accomplished by the frequency of induced CTLs specific to both gp70 and β-galactosidase assessed by using pentameric assay. Among the fusion vaccines tested, semiallogeneic DC/TC hybrids induced the highest ratio of Th1 cytokine IFN-γ to Th2 cytokine IL-10. In addition, allogeneic or semiallogeneic DC/TC hybrids elicited a significantly stronger NK activity than syngeneic DC/TC hybrids. These findings suggest that in clinical settings, DCs derived from a healthy donor (which are generally characterized as more semiallogeneic than allogeneic) may be more capable than autologous DCs of inducing promising anti-tumor effects in vaccinations with DC/TC hybrids.

Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5:1249–1255PubMedCrossRef

Porgador A, Gilboa E (1995) Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182:255–260PubMedCrossRef

Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296PubMedCrossRef

Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472PubMedCrossRef

Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482–9487PubMedCrossRef

Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT (1995) Bone-marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1:1297–1302PubMedCrossRef

Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177–1182PubMedCrossRef

Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B (1996) Vaccination of patients with B-cell lymphoma using autologus antigen-pulsed dendritic cells. Nat Med 2:52–58PubMedCrossRef

Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat med 4:328–332PubMedCrossRef

10.

Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H (1999) Infusion of dendritic cells pulsed with HLA-A2 specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:71–78CrossRef

11.

Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski K, Bhardwaj N, Piniero L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458PubMed

12.

Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108PubMed

13.

Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, Blanck JP, Johnston DA, Palu cka AK. Fay J (2005) Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type i interferon. J Immunother 28:505–516PubMedCrossRef

14.

Nestle FO, Alijagic S, Gilliet M, Sun YS, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332PubMedCrossRef

15.

Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini J, Banchereaux J, Palucka AK (2000) Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192:1535–1544PubMedCrossRef

16.

Gong J, Chen DS, Kashiwaba M, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558–561PubMedCrossRef

17.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F (2004) Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53:963–977PubMedCrossRef

18.

Wang J, Saffold S, Cao X, Krauss J, Chen W (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161:5516–5524PubMed

19.

Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97:2715–2718PubMedCrossRef

20.

Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F (2002) Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51:299–310PubMedCrossRef

21.

Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D (2004) Fusion cell vaccination of patients with metastatic breast and renal cell cancer induces immunological and clinical responses. Clin Cancer Res 10:4699–4708PubMedCrossRef

22.

Koido S, Nikrui N, Obana M, Xia J, Tanaka Y, Liu C, Durfee JK, Lerner A, Gong J (2005) Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol 99:462–471PubMedCrossRef

23.

Gong J, Nikrui N, Chen DS, Koido S, Wu ZK, Tanaka Y, Cannistra S, Avigan D, Kufe D (2000) Fusions of human ovarian carcinoma cells with autologus or allogenic dendritic cells induce antitumor immunity. J Immunol 165:1705–1711PubMed

24.

Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K, Sakakibara T, Koinuma D, Kikuchi T, Tazawa R, Maemondo M, Hagiwara K, Saijo Y, Nukiwa T (2005) Vaccination of dendritic cells loaded with Interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 11:58–66PubMed

25.

Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J (2001) Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101:192–200PubMedCrossRef

26.

Silders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM (2003) Induction of specific antitumor immunity in the mouse with electrofusion product of tumor cells and dendritic cells. Mol Ther 7:498–505CrossRef

27.

Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332–336PubMedCrossRef

28.

Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasazuki T (1994) Nomenclature for factors of the HLA system, 1994. Hum Immunol 41:1–20PubMedCrossRef

29.

Moalic V, Ferec C (2005) HLA typing, analysis methods, and clinical applications. Presse Med 34:1101–1108PubMed

30.

Ali S, Ahmad M, Lynam J, Rees RC, Brown N (2004) Trafficking of tumor peptide-specific cytotoxic T lymphocytes into tumor microcirculation. Int J Cancer 10:239–244CrossRef

31.

Lutz MB, Kukutsch N, Ogilvie ALJ, Rossner S, Koch F, Romani N, Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77–92PubMedCrossRef

32.

Harris N, Campbell C, Le Gros G, Ronchese F (1997) Blockade of CD28/B7 co-stimulation by mCTLA4-Hgamma1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Eur J Immunol 27:155–161PubMedCrossRef

33.

Ferlazzo G, Semino C, Spaggiari GM, Meta M, Mingari MC, Melioli G (2000) Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol 12:1741–1747PubMedCrossRef

34.

Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, Sparbier K, Sterry W, Walden P (2005) Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23:2367–2373PubMedCrossRef

35.

Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R (2002) The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25:421–428PubMedCrossRef

36.

Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344PubMedCrossRef

37.

Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinber AM, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG (2003) Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14:483–494PubMedCrossRef

38.

Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA (2001) Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 166:973–981PubMed

39.

Fabre JW (2001) The allogeneic response and tumor immunity. Nat Med 7:649–652PubMedCrossRef

40.

Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB (2005) Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42:535–539PubMedCrossRef

41.

Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA (2006) NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 55:1122–1131PubMedCrossRef

42.

Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G (2005) Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 11:7891–7900PubMedCrossRef

43.

Iinuma H, Okinaga K, Fukushima R, Inaba T, Iwasaki K, Okinaga A, Takahashi I, Kaneko M (2006) Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J Immunol 176:3461–3469PubMed

44.

Yamazaki S, Patel M, Harper A, Bonito A, Fukuyama H, Pack M, Tarbell KV, Talmor M, Ravetch JV, Inaba K, Steinman RM (2006) Effective expansion of alloantigen-specific Foxp3⁺CD25⁺CD4⁺ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci USA 103:2758–2763PubMedCrossRef

45.

Prasad SJ, Farrand KJ, Matthews SA, Chang LH, McHugh RS, Ronchese F (2005) Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4⁺CD25⁺regulatory T cells. J Immunol 174:90–98PubMed

46.

Meirvenne SV, Dullaers M, Heirman C, Straetman L, Michiels A, Thielemans K (2005) In vivo depletion of CD4⁺CD25⁺ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells. Mol Ther 12:922–932PubMedCrossRef

47.

Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S (2004) Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27:265–272PubMedCrossRef

48.

Kao JY, Zhang M, Chen CM, Chen JJ (2005) Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 101:154–159PubMedCrossRef

Title: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma
Authors: Takashi Yasuda
Takashi Kamigaki
Kentaro Kawasaki
Tetsu Nakamura
Masashi Yamamoto
Kiyonori Kanemitsu
Shiro Takase
Daisuke Kuroda
Yongsik Kim
Tetsuo Ajiki
Yoshikazu Kuroda
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0252-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2007

MIP3 alpha stimulates the migration of Langerhans cells in models of human papillomavirus (HPV)-associated (pre)neoplastic epithelium

Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location

Mannan-binding lectin (MBL) in women with tumours of the reproductive system

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression

CD8+ T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer